Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds Under Its SciSparc Ltd Collaboration
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds Under Its SciSparc Ltd Collaboration
Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has submitted three patent applications under the international Patent Cooperation Treaty ("PCT"), as part of its ongoing collaboration with SciSparc Ltd. (NASDAQ:SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
Clearmind Medicine Inc.（納斯達克證券交易所代碼：CMND）（FSE：CWY）（“Clearmind” 或 “公司”）是一家生物技術公司，專注於發現和開發新型迷幻藥衍生療法以解決治療不足的重大健康問題。該公司今天宣佈，它已根據《國際專利合作條約》（“PCT”）提交了三項專利申請，這是其與ScisPARC Ltd（納斯達克）持續合作的一部分。Q: SPRC)（“ScisPARC”），一家處於臨床階段的專業製藥公司，專注於開發治療中樞神經疾病的療法系統。
譯文內容由第三人軟體翻譯。